Compare Comfort Systems USA Inc (FIX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs TG Therapeutics Inc — how do they compare? Comfort Systems USA Inc trades at $1,751.78 (market cap $59.41B), while TG Therapeutics Inc trades at $50.42 (market cap $7.64B). The key difference: Comfort Systems USA Inc is far larger — about 7.8× TG Therapeutics Inc's market cap, and Comfort Systems USA Inc pays a 0.21% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FIX | TGTX | |
|---|---|---|
Market Cap | $59.41B | $7.64B |
Sector | Technology | Health |
52-Week High | $2.07K | $59.06 |
52-Week Low | $680.86 | $26.94 |
Enterprise Value | $57.88B | $7.84B |
Dividend Yield | 0.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,750.90, up 4.54% with strong earnings momentum as Q2 2026 EPS of $12.53 beat expectations by 20%. The stock shows bearish technical signals but maintains robust fundamentals with 55.29% ROE and record backlog driven by data center demand. Recent news highlights margin expansion and institutional position adjustments.
Outlook remains positive given analyst consensus price target of $2,170 (24% upside), though premium valuation (P/E 41.55) and execution risks warrant caution. Key opportunities include AI-driven data center growth, while risks involve capacity constraints and market volatility near technical resistance.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
